The Canada Pension Plan Investment Board and the Public Sector Pension Investment Board are participating in a $390-million series-D round of financing for Grail Inc., a U.S. health-care company focused on cancer testing.

The financing is aimed at boosting the company’s balance sheet to support its continued development, as well as the commercialization of its cancer testing method.

Read: CPPIB invests in cancer drug royalties, food manufacturing

“GRAIL is making significant progress with our blood-based, multi-cancer early detection test,” said Hans Bishop, chief executive officer at Grail, in a press release. “Nearly 80 per cent of cancer deaths result from cancers for which there is no screening test today and Grail’s mission is to change that through the early detection and localization of more than 50 cancers.”

Copyright © 2020 Transcontinental Media G.P. Originally published on benefitscanada.com

Join us on Twitter

Add a comment

Have your say on this topic! Comments that are thought to be disrespectful or offensive may be removed by our Benefits Canada admins. Thanks!

* These fields are required.
Field required
Field required
Field required